ABIFINA
CONTATO
ASSOCIE-SE
LOGIN
  • Sobre
    • Quem somos
    • Código de Conduta Ética
    • Comitês
    • Estatuto Social
    • Estrutura organizacional
    • Galeria dos Presidentes
    • História
    • Segmentos da Química Fina
  • Prêmios
    • Prêmio Alcebíades de Mendonça Athayde
    • Prêmio Denis Barbosa
  • Associados
  • Notícias
    • ABIFINA na mídia
    • Associado em foco
    • Acontece na ABIFINA
    • Outras Notícias
  • Eventos
  • Produtos e serviços
    • ABIFINA Divulga
    • Clipping Diário de Notícias
    • Estatísticas
    • Centro de Monitoramento de Patentes
      • MPP Agro
      • MPP BIO
      • MPP Cannabis
      • MPP FDA
      • MPP FDA Biossimilares
      • MPP Saúde Animal
      • MPP SUS
    • Observatório de Ilegais
    • Panorama Regulatório Internacional
    • Propriedade Intelectual
      • Processo Administrativo de Nulidade (PAN)
      • Redação de Patentes
      • Relatórios de Patenteabilidade
      • Subsídios Técnicos
    • Resumo Semanal
  • Publicações
    • Revista FACTO
    • Todas as publicações
CONTATO

Repositório Covid-19

10/08/2021

Longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients in Thailand

Serological assays to detect antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might contribute to confirming the suspected coronavirus...

10/08/2021

A nanotechnological approach in the current therapy of COVID-19: model drug oseltamivir-phosphate loaded PLGA nanoparticles targeted with spike protein binder peptide of SARS-CoV-2

Coronavirus disease 2019 (COVID-19) is today’s most serious epidemic disease threatening the human race. The initial therapeutic approach of SARS-CoV-2...

10/08/2021

Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020

The safety profile of remdesivir, conditionally approved for COVID-19, was limited at its 2020 introduction. Adverse drug reactions (ADRs) for...

10/08/2021

Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study

The Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) is a prospective longitudinal study designed to enroll 1000 hospitalized patients with...

10/08/2021

Bioactive recombinant human oncostatin M for NMR-based screening in drug discovery

Oncostatin M (OSM) is a pleiotropic, interleukin-6 family inflammatory cytokine that plays an important role in inflammatory diseases, including inflammatory...

10/08/2021

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

A previous efficacy trial found benefit from inhaled budesonide for COVID-19 in patients not admitted to hospital, but effectiveness in...

09/08/2021

Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that is spreading rapidly, which seriously impacts global public...

09/08/2021

The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology

The current coronavirus disease 2019 (COVID-19) pandemic is the first to apply whole-genome sequencing near to real time, with over...

08/08/2021

A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency

The SARS-CoV-2 receptor angiotensin converting enzyme 2 (ACE2) was previously engineered into a high affinity tetravalent format (ACE2-Fc-TD) that is...

04/08/2021

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Thrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose...

04/08/2021

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal antibodies casirivimab and imdevimab, has been shown to markedly reduce...

03/08/2021

The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19

The coronavirus disease 2019 (COVID-19) pandemic has caused significant morbidity and mortality on a global scale. The etiologic agent, severe...

  • « anterior
  • 1
  • 2
  • 3
  • 4
  • …
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • próxima »
  • Sobre
  • Associados
  • Notícias
  • Eventos
  • Estatísticas
  • Publicações
  • Contato
  • Política de Privacidade
Av. Churchill, 129 • Sala 1201 • Centro • Rio de Janeiro • RJ
+55 21 3125-1400 [email protected]

Todos os direitos reservados © 2025 - ABIFINA

Desenvolvido por Conceito Comunicação Integrada
Login
Esqueci a senha